Xbrane Eyes Positive Cash Flow In 2024 – But Out-Licensing Oncology Key

Swedish Firm In ‘Active Discussions With Potential Partners,’ Deal Possible In 2023

 
• By Dean Rudge
  
• Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products